Lon S. Schneider
Psychiatry and Mental health · 2005–2021
A researcher in the Science corpus: 15 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Psychiatry and Mental health — 213 citations into it
Whom Lon S. Schneider trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- P. Insel (in Psychiatry and Mental health)
- Karen Stevens Dagerman (in Psychiatry and Mental health)
Papers from Lon S. Schneider's perspective
Ordered by how strongly the researchers Lon S. Schneider trusts endorse each paper. Same corpus, a different order for every researcher.
- Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory (Journal of Neuroscience)
- Quantifying heterogeneity in a meta‐analysis (Statistics in Medicine)
- Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders (Nature Reviews Neuroscience)
- Propagation of Tau Misfolding from the Outside to the Inside of a Cell* (Journal of Biological Chemistry)
- Neurovascular regulation in the normal brain and in Alzheimer's disease (Nature Reviews Neuroscience)
- Classification of primary progressive aphasia and its variants (Neurology)
- METAL: fast and efficient meta-analysis of genomewide association scans (Bioinform.)
- Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia (Journal of the American Medical Association (JAMA))
- Primary age-related tauopathy (PART): a common pathology associated with human aging (Acta Neuropathologica)
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (International Journal of Behavioral Medicine)
Their papers
- Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease (2011) — 1,887 citations
- Four distinct trajectories of tau deposition identified in Alzheimer’s disease (2021) — 636 citations
- Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group (2021) — 763 citations
- Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) — 7,984 citations
- APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline (2020) — 1,053 citations
- Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction (2019) — 1,438 citations
- Dementia prevention, intervention, and care. (2017) — 4,936 citations
- Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) — 1,062 citations
- Defeating Alzheimer's disease and other dementias: a priority for European science and society. (2016) — 1,473 citations
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. (2014) — 3,079 citations
- Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014 (2014) — 622 citations
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease (2009) — 627 citations
- Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. (2006) — 899 citations
- Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. (2006) — 823 citations
- Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. (2005) — 1,676 citations